Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 377

1.

National trends in oral anticoagulant use in the United States, 2007 to 2011.

Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC.

Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):615-21. Epub 2012 Sep 4.

2.

National Trends in Ambulatory Oral Anticoagulant Use.

Barnes GD, Lucas E, Alexander GC, Goldberger ZD.

Am J Med. 2015 Dec;128(12):1300-5.e2. doi: 10.1016/j.amjmed.2015.05.044. Epub 2015 Jul 2.

3.

Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.

Steinberg BA, Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC, Gersh B, Mahaffey KW, Kowey PR, Ezekowitz MD, Singer DE, Thomas L, Peterson ED, Hylek EM; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients.

J Am Heart Assoc. 2013 Nov 25;2(6):e000535. doi: 10.1161/JAHA.113.000535.

4.

Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis.

AbuDagga A, Stephenson JJ, Fu AC, Kwong WJ, Tan H, Weintraub WS.

BMC Health Serv Res. 2014 Jul 17;14:310. doi: 10.1186/1472-6963-14-310.

5.

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.

Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND.

BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857.

6.

Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.

Clemens A, Peng S, Brand S, Brueckmann M, Kansal A, Lim J, Noack H, Sander S, Sorensen S.

Am J Cardiol. 2014 Sep 15;114(6):849-55. doi: 10.1016/j.amjcard.2014.06.015. Epub 2014 Jul 2.

7.

Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.

Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ, Spettell CM, Brennan TA, Matlin OS, Avorn J, Choudhry NK.

Am J Med. 2014 Nov;127(11):1075-82.e1. doi: 10.1016/j.amjmed.2014.05.013. Epub 2014 May 21.

PMID:
24859719
8.

Increasing off-label use of antipsychotic medications in the United States, 1995-2008.

Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS.

Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):177-84. doi: 10.1002/pds.2082. Epub 2011 Jan 6.

9.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.

Chang AM, Ho JC, Yan BP, Yu CM, Lam YY, Lee VW.

Clin Cardiol. 2013 May;36(5):280-5. doi: 10.1002/clc.22112. Epub 2013 Mar 14.

10.

Recent national patterns of warfarin use in atrial fibrillation.

Stafford RS, Singer DE.

Circulation. 1998 Apr 7;97(13):1231-3.

11.

Population-based evaluation of the management of antithrombotic therapy for atrial fibrillation.

Anderson DR, Gardner MJ, Putnam W, Jassal D, Brownell B, Flowerdew G, Nagpal S, Thompson K, Cox JL.

Can J Cardiol. 2005 Mar;21(3):257-66.

PMID:
15776115
12.

Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.

Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW.

Circulation. 2015 Mar 17;131(11):972-9. doi: 10.1161/CIRCULATIONAHA.114.014113. Epub 2015 Jan 16.

13.

Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation.

Maddox W, Kay GN, Yamada T, Osorio J, Doppalapudi H, Plumb VJ, Gunter A, McElderry HT.

J Cardiovasc Electrophysiol. 2013 Aug;24(8):861-5. doi: 10.1111/jce.12143. Epub 2013 Apr 11.

PMID:
23577951
14.

Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.

Chevalier J, Delaitre O, Hamm├Ęs F, de Pouvourville G.

Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):381-90. doi: 10.1016/j.acvd.2014.04.009. Epub 2014 Jun 24.

15.

Catheter ablation of atrial fibrillation: the need for studies to assess the efficacy and safety of novel anticoagulants.

Naccarelli GV, Gonzalez MD.

J Interv Card Electrophysiol. 2013 Jan;36(1):3-4. doi: 10.1007/s10840-012-9720-3. Epub 2012 Sep 28. No abstract available.

PMID:
23054126
16.

[Dabigatran, a new oral anticoagulant].

Uchiyama S.

Brain Nerve. 2011 Apr;63(4):411-5. Review. Japanese.

PMID:
21441645
17.

Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.

Martinez C, Katholing A, Wallenhorst C, Freedman SB.

Thromb Haemost. 2016 Jan;115(1):31-9. doi: 10.1160/TH15-04-0350. Epub 2015 Aug 6.

PMID:
26246112
18.

Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies.

Steinberg BA, Hasselblad V, Atwater BD, Bahnson TD, Washam JB, Alexander JH, Daubert JP, Piccini JP.

J Interv Card Electrophysiol. 2013 Sep;37(3):213-21. doi: 10.1007/s10840-013-9813-7. Epub 2013 Jul 24.

19.

Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation.

Haines DE, Mead-Salley M, Salazar M, Marchlinski FE, Zado E, Calkins H, Yarmohammadi H, Nademanee K, Amnueypol M, Skanes AC, Saklani P.

J Interv Card Electrophysiol. 2013 Sep;37(3):233-9. doi: 10.1007/s10840-013-9800-z. Epub 2013 Jun 6.

PMID:
23740224
20.

Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.

Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA.

Europace. 2014 Oct;16(10):1443-9. doi: 10.1093/europace/euu196. Epub 2014 Aug 12.

Supplemental Content

Support Center